At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
XTL SPDR S&P Telecom ETF
Post-Mkt 06-17 16:01:38 EDT
221.42
-2.61
-1.17%
盘后221.49
+0.07+0.03%
16:00 EDT
High225.55Low221.23Vol118.32K
Open225.00D1 Closing224.03Amplitude1.93%
Mkt Cap763.90MTradable Cap763.90MTotal Shares3.45M
T/O26.44MT/O Rate3.43%Tradable Shares3.45M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

SpaceX's Wireless Ambitions May Not Disrupt US Telecoms Soon, BNP Paribas Analysis Suggests
Stock News  ·  06-15 08:59
SpaceX's Wireless Ambitions May Not Disrupt US Telecoms Soon, BNP Paribas Analysis Suggests
XTL Biopharmaceuticals Gets Nasdaq Noncompliance Notice
MT Newswires Live  ·  05-23
XTL Biopharmaceuticals Gets Nasdaq Noncompliance Notice
XTL Biopharmaceuticals Faces Added Nasdaq Delisting Risk Over Late 2025 Annual Report
TIPRANKS  ·  05-23
XTL Biopharmaceuticals Faces Added Nasdaq Delisting Risk Over Late 2025 Annual Report
XTL Announces Receipt of Staff Delist Determination from Nasdaq
GlobeNewswire  ·  05-23
XTL Announces Receipt of Staff Delist Determination from Nasdaq
XTL Biopharmaceuticals Calls June 22, 2026 Meeting to Approve Psyga Bio Acquisition and Capital Raise
TIPRANKS  ·  05-16
XTL Biopharmaceuticals Calls June 22, 2026 Meeting to Approve Psyga Bio Acquisition and Capital Raise
The stock market is breaking the rules of the inflation playbook. Here is what is different this time
Dow Jones  ·  05-14
The stock market is breaking the rules of the inflation playbook. Here is what is different this time
A look at which assets are following the script, and which aren't, on day 75 of the war
Dow Jones  ·  05-14
A look at which assets are following the script, and which aren't, on day 75 of the war
XTL Biopharmaceuticals Wins Conditional Nasdaq Listing Reprieve Tied to Psyga Bio Deal
TIPRANKS  ·  05-07
XTL Biopharmaceuticals Wins Conditional Nasdaq Listing Reprieve Tied to Psyga Bio Deal
XTL Biopharmaceuticals to Acquire PsygaBio in All-Stock Deal to Expand Psychedelic Drug Pipeline
TIPRANKS  ·  04-29
XTL Biopharmaceuticals to Acquire PsygaBio in All-Stock Deal to Expand Psychedelic Drug Pipeline
XTL Biopharmaceuticals to Acquire Psyga Bio, Establishing a Leading Psychedelic Biotechnology Platform with Advanced Clinical Pipeline, Licensed GMP Manufacturing and Proprietary Psilocybin Technologies
GlobeNewswire  ·  04-29
XTL Biopharmaceuticals to Acquire Psyga Bio, Establishing a Leading Psychedelic Biotechnology Platform with Advanced Clinical Pipeline, Licensed GMP Manufacturing and Proprietary Psilocybin Technologies
XTL Biopharmaceuticals trading halted, news pending
TIPRANKS  ·  03-25
XTL Biopharmaceuticals trading halted, news pending
XTL Biopharmaceuticals to Change ADS Ratio
MT Newswires Live  ·  03-21
XTL Biopharmaceuticals to Change ADS Ratio
XTL Biopharmaceuticals to Implement One-for-Four ADS Reverse Split Effective March 25, 2026
TIPRANKS  ·  03-21
XTL Biopharmaceuticals to Implement One-for-Four ADS Reverse Split Effective March 25, 2026
Beyond Air announces termination of NeuroNOS agreement with XTL
TIPRANKS  ·  03-10
Beyond Air announces termination of NeuroNOS agreement with XTL
XTL Biopharmaceuticals Faces Nasdaq Delisting After “Public Shell” Determination
TIPRANKS  ·  02-28
XTL Biopharmaceuticals Faces Nasdaq Delisting After “Public Shell” Determination
XTL Biopharmaceuticals gets delisting letter from Nasdaq, to request hearing
TIPRANKS  ·  02-28
XTL Biopharmaceuticals gets delisting letter from Nasdaq, to request hearing
XTL Announces Receipt of Staff Delist Determination from Nasdaq and Plans to Request Hearing
GlobeNewswire  ·  02-28
XTL Announces Receipt of Staff Delist Determination from Nasdaq and Plans to Request Hearing
XTL Biopharmaceuticals Advances NeuroNOS Acquisition and Plans $2 Million Private Placement to Address Nasdaq Equity Deficiency
TIPRANKS  ·  01-28
XTL Biopharmaceuticals Advances NeuroNOS Acquisition and Plans $2 Million Private Placement to Address Nasdaq Equity Deficiency
XTL Biopharmaceuticals Faces Subsidiary Insolvency Filing, Reviews $1.5 Million Loan Exposure
TIPRANKS  ·  01-24
XTL Biopharmaceuticals Faces Subsidiary Insolvency Filing, Reviews $1.5 Million Loan Exposure
XTL Biopharmaceuticals Flags Nasdaq Equity Deficiency, Given Deadline to Regain Compliance
TIPRANKS  ·  01-24
XTL Biopharmaceuticals Flags Nasdaq Equity Deficiency, Given Deadline to Regain Compliance

Introduction

Company Name.
SPDR S&P Telecom ETF
Affiliated Markets:
ARCA
Listing Date:
--
Main Business:
In seeking to track the performance of the S&P Telecom Select Industry Index (the "index"), the fund employs a sampling strategy. It generally invests substantially all, but at least 80%, of its total assets in the securities comprising the index. The index represents the telecommunications segment of the S&P Total Market Index ("S&P TMI").
Issue price:
--